NEXT DAY DISCLOSURE RETURN

NEXT DAY DISCLOSURE RETURN

NEXT DAY DISCLOSURE RETURN

NEXT DAY DISCLOSURE RETURN

NEXT DAY DISCLOSURE RETURN

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 2024

VOLUNTARY ANNOUNCEMENT - POSITIVE RESULTS FROM PHASE III STUDY OF BENMELSTOBART INJECTION IN COMBINATION WITH CHEMOTHERAPY FOLLOWED BY SEQUENTIAL COMBINATION WITH ANLOTINIB HYDROCHLORIDE CAPSULES VERSUS TISLELIZUMAB INJECTION IN COMBINATION WITH CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF ADVANCED SQUAMOUS NON-SMALL CELL LUNG CANCER

VOLUNTARY ANNOUNCEMENT - PERMISSION OBTAINED TO SUBMIT MARKETING APPLICATION FOR THE INDICATION OF BENMELSTOBART INJECTION IN COMBINATION WITH ANLOTINIB HYDROCHLORIDE CAPSULES FOR TREATMENT OF ADVANCED ALVEOLAR SOFT PART SARCOMA